Clinical trial
A Pilot Study of Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
NCT04255836 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
- Lead sponsor
- Zhejiang Cancer Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 30, 2020
- Completion date
- July 30, 2023
- Enrollment
- 35 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.